GlaxoSmithKline plc (LON:GSK) had its target price decreased by J P Morgan Chase & Co from GBX 1,750 ($22.60) to GBX 1,570 ($20.28) in a research note released on Wednesday morning, MarketBeat.com reports. J P Morgan Chase & Co currently has a neutral rating on the stock.
Other analysts also recently issued reports about the company. Bryan, Garnier & Co reissued a buy rating and issued a GBX 1,750 ($22.60) price objective on shares of GlaxoSmithKline plc in a research note on Wednesday, May 31st. UBS AG set a GBX 1,600 ($20.66) price objective on GlaxoSmithKline plc and gave the stock a neutral rating in a research note on Monday, May 29th. Goldman Sachs Group, Inc. (The) reissued a buy rating and issued a GBX 1,900 ($24.54) price objective on shares of GlaxoSmithKline plc in a research note on Wednesday, May 31st. Liberum Capital reissued a buy rating and issued a GBX 1,900 ($24.54) price objective on shares of GlaxoSmithKline plc in a research note on Wednesday, June 14th. Finally, Deutsche Bank AG reissued a hold rating and issued a GBX 1,720 ($22.21) price objective on shares of GlaxoSmithKline plc in a research note on Friday, June 30th. Four equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of GBX 1,705.90 ($22.03).
GlaxoSmithKline plc (LON:GSK) opened at 1454.00 on Wednesday. The company’s market capitalization is GBX 71.07 billion. The firm has a 50-day moving average price of GBX 1,507.18 and a 200-day moving average price of GBX 1,610.52. GlaxoSmithKline plc has a 1-year low of GBX 1,446.50 and a 1-year high of GBX 1,745.56.
ILLEGAL ACTIVITY WARNING: “J P Morgan Chase & Co Trims GlaxoSmithKline plc (GSK) Target Price to GBX 1,570” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://transcriptdaily.com/2017/09/17/j-p-morgan-chase-co-trims-glaxosmithkline-plc-gsk-target-price-to-gbx-1570.html.
The business also recently declared a dividend, which will be paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th will be issued a GBX 19 ($0.25) dividend. This represents a dividend yield of 1.23%. The ex-dividend date is Thursday, August 10th.
In related news, insider Manvinder Singh Banga purchased 2,267 shares of the business’s stock in a transaction dated Wednesday, July 26th. The stock was purchased at an average cost of GBX 1,599 ($20.65) per share, with a total value of £36,249.33 ($46,815.61). Also, insider Patrick Vallance purchased 861 shares of the business’s stock in a transaction dated Friday, July 14th. The stock was bought at an average cost of GBX 1,618 ($20.90) per share, with a total value of £13,930.98 ($17,991.71). Insiders bought 3,152 shares of company stock valued at $5,055,023 over the last ninety days.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.